^
    Back
    Association details:
    Biomarker:KRAS G12R
    Cancer:Gastric Cancer
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    J Clin Oncol
    Title:

    KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation

    Excerpt:
    Therefore, the PTEN mutation was not directly responsible for imatinib resistance, but likely created a biologic state that was permissive for KRAS G12R– transforming activity, with KRAS G12R being a known imatinibresistance mechanism.
    DOI:
    10.1200/JCO.2013.48.7488